Arch Therapeutics Co-Founder Rutledge Ellis-Behnke Delivers Keynote at Nanomaterials Technology Transfer Conference in Corfu,...
16 Juli 2013 - 3:00PM
Marketwired
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch"
or the "Company"), a life science company and developer of AC5™, a
novel product aimed at controlling bleeding and fluid loss in order
to provide faster and safer surgical and interventional care, is
pleased to advise that co-founding and inventing scientist, Dr.
Rutledge Ellis-Behnke, delivered a keynote lecture titled
"Translating Nanomedicine: Molecular medical devices from Nano
Neuro Knitting to Immediate Hemostasis to Cancer Stem Cell Arrest"
in Corfu, Greece at the Technology Transfer Workshop: From the Lab
to the Marketplace.
Dr. Ellis-Behnke was instrumental in discovering the hemostatic
and other barrier properties of self-assembling peptides that could
make future surgery and interventional care faster and safer
through the development and proposed commercialization of the
Company's flagship product candidate known as AC5™. The product is
based on a self-assembling peptide solution that creates a
physical, mechanical barrier, which could be applied to bleeding
organs or wounds to seal leaking blood and other fluids.
Dr. Ellis-Behnke presented during a day-long special workshop,
addressing nanotechnology transfer, which was part of a larger
four-day conference, the 4th International Conference for
Nanoparticles and Nanomaterials to Nanodevices and Nanosystems,
which reviewed the current state-of-the-art in nanoscience and
nanotechnology, and identifies challenging and rewarding research
directions.
Ellis-Behnke talked about his discovery of new molecular medical
devices and how they will change medicine and the entire healthcare
system. "Controlling the healing process is critical for the
recovery of any injury, especially burn trauma," Ellis-Behnke
continues, "First a barrier must be created to stop bleeding. In a
surgical setting, we've shown that we can stop bleeding in small
and large animals in less than 15 seconds, in multiple tissues, as
well as a variety of different wounds, using a self-assembling
peptide that creates a barrier and incorporates it into the
surrounding tissue to form an extracellular matrix. This is all
achieved without clotting and we've found that it does not induce
an immune response."
An added benefit of the nanomaterial is that it is optically
transparent. "Placing it on a wound not only stops the bleeding
quickly and creates a barrier; it also provides a clear view of the
surgical field while operating through it."
"This technology will impact the operating room in a fundamental
way through the reduction in procedure time, along with the ability
to control the environment so operations can be performed in less
than optimal conditions while maintaining surgical field
integrity," said Ellis-Behnke. "The time to perform an operation
could potentially be reduced by up to 50 percent."
Additional details regarding Arch Therapeutics, Inc., its
business, agreements and related matters are filed as part of the
Company's continuous public disclosure as a reporting issuer under
the Securities Exchange Act of 1934 filed with the Securities and
Exchange Commission ("SEC"), and are available at the SEC's website
at www.sec.gov. For more information, visit our website at
www.archtherapeutics.com.
About Arch Therapeutics, Inc. (OTCQB:
ARTH) Arch Therapeutics, Inc. (OTCQB: ARTH) is a medical device
company developing a novel approach to stop bleeding (hemostasis)
and control leaking (sealant) during surgery and trauma care.
Arch's goal is to develop and commercialize products based on our
innovative technology platform that make surgery and interventional
care faster and safer for patients. Arch's flagship development
stage product candidate known as AC5™ is being designed to
elegantly achieve hemostasis in minimally invasive and open
surgical procedures. Find out more at www.archtherapeutics.com.
Notice Regarding Forward-Looking
Statements This news release contains "forward-looking
statements" as that term is defined in Section 27(a) of the
Securities Act of 1933, as amended, and Section 21(e) of the
Securities Exchange Act of 1934, as amended. Statements in this
press release that are not purely historical are forward-looking
statements and include any statements regarding beliefs, plans,
expectations or intentions regarding the future. Such
forward-looking statements include, among other things, references
to novel technologies and methods, our business and product
development plans and projections, or market information. Actual
results could differ from those projected in any forward-looking
statements due to numerous factors. Such factors include, among
others, the inherent uncertainties associated with developing new
products or technologies and operating as a development stage
company, our ability to retain important members of our management
team and attract other qualified personnel, our ability to raise
the additional funding we will need to continue to pursue our
business and product development plans, our ability to develop and
commercialize products based on our technology platform, and market
conditions. These forward-looking statements are made as of the
date of this news release, and we assume no obligation to update
the forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements. Although we believe that any beliefs, plans,
expectations and intentions contained in this press release are
reasonable, there can be no assurance that any such beliefs, plans,
expectations or intentions will prove to be accurate. Investors
should consult all of the information set forth herein and should
also refer to the risk factors disclosure outlined in the reports
and other documents we file with the SEC, available at
www.sec.gov.
On Behalf of the Board,
Terrence W. Norchi, MD. Arch Therapeutics, Inc.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: ARTH Investor Relations Toll Free:
+1-855-340-ARTH (2784) (US and Canada) Email:
investors@archtherapeutics.com Website:
www.archtherapeutics.com
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jul 2023 bis Jul 2024